Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

STX 478

Next Previous
Drug Profile

STX 478

Alternative Names: LY-4064809; ST-814; STX-478; STX-H1047-PI3Ka inhibitors - Scorpion Therapeutics

Latest Information Update: 25 Nov 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Scorpion Therapeutics
  • Developer Eli Lilly and Company; Scorpion Therapeutics
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Phosphatidylinositol 3 kinase alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Breast cancer
  • Phase I/II Solid tumours

Most Recent Events

  • 27 Oct 2025 Phase-III clinical trials in Breast cancer (Combination therapy, Metastatic disease, First-line therapy) in USA (PO) (NCT07174336)
  • 24 Oct 2025 Phase-I clinical trials in Solid tumours (In volunteers) in Singapore (PO) (NCT07247357)
  • 20 May 2025 Eli Lilly and Company initiates enrolment in the phase I (In volunteers) trial in the US (NCT06991179)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top